...
首页> 外文期刊>European journal of pharmaceutical sciences >In vitro & in vivo targeting behaviors of biotinylated Pluronic F127/poly(lactic acid) nanoparticles through biotin-avidin interaction
【24h】

In vitro & in vivo targeting behaviors of biotinylated Pluronic F127/poly(lactic acid) nanoparticles through biotin-avidin interaction

机译:通过生物素-亲和素相互作用的生物素化的Pluronic F127 /聚乳酸纳米颗粒的体外和体内靶向行为

获取原文
获取原文并翻译 | 示例

摘要

Biotinylated Pluronic F127/poly(lactic acid) block copolymers (B-F127-PLA) were successfully synthesized previously by our group. In the present study, the release behaviors of paclitaxel-loaded B-F127-PLA nanoparticles and their targeting properties to human ovarian carcinoma cells were investigated. Paclitaxel (pac) loaded in B-F127-PLA nanoparticles shows an initial burst release in the first 6 h and followed by a slow release. The in vitro targeting behaviors of B-F127-PLA nanoparticles against human ovarian cancer cells (OVCAR-3, SKOV-3) were investigated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) tests and fluorescence microscopy (FM) technique. Targeting was based on a three-step biotin-avidin targeting approach using biotinylated anti-CA125 antibody specific for the CA-125 antigen that is highly expressed on OVCAR-3 cells but not expressed on SKOV-3 cells. MTT results show that the anticancer effect of paclitaxel in B-F127-PLA nanoparticles over OVCAR-3 cells was stronger than that over SKOV-3 cells, indicating that B-F127-PLA nanoparticles were delivered more effectively to OVCAR-3 cells than to SKOV-3 cells. The targeting behaviors of B-F127-PLA nanoparticles were further confirmed by FM technique. The intracellular distribution of B-F127-PLA nanoparticles was also studied using a triple-labeling method. It was observed that B-F127-PLA nanoparticles are mainly localized within the cytoplasm of OVCAR-3 cells. The in vivo antitumor efficacy of pac-loaded B-F127-PLA nanoparticles by three-step method as measured by change in tumor volume of OVCAR-3 implanted in Balb/C nude mice was greater than that by one-step method.
机译:我们小组先前已成功合成了生物素化的Pluronic F127 /聚乳酸嵌段共聚物(B-F127-PLA)。在本研究中,研究了紫杉醇负载的B-F127-PLA纳米粒子的释放行为及其对人卵巢癌细胞的靶向特性。负载在B-F127-PLA纳米颗粒中的紫杉醇(pac)在最初的6小时内显示出最初的突释释放,然后缓慢释放。通过3-(4,5-二甲基噻唑-2-基)-2,5-二苯基溴化四唑研究了B-F127-PLA纳米粒子对人卵巢癌细胞(OVCAR-3,SKOV-3)的体外靶向行为(MTT)测试和荧光显微镜(FM)技术。靶向基于三步生物素-抗生物素蛋白靶向方法,该方法使用对CA-125抗原具有特异性的生物素化抗CA125抗体,该抗体在OVCAR-3细胞上高度表达,但在SKOV-3细胞上不表达。 MTT结果表明,紫杉醇对B-F127-PLA纳米颗粒的抗癌作用强于OVCAR-3细胞,其抗癌作用强于SKOV-3细胞,表明B-F127-PLA纳米颗粒对OVCAR-3细胞的抗癌作用强于对OVCAR-3细胞。 SKOV-3细胞。 FM技术进一步证实了B-F127-PLA纳米粒子的靶向行为。还使用三标记方法研究了B-F127-PLA纳米颗粒的细胞内分布。观察到B-F127-PLA纳米颗粒主要位于OVCAR-3细胞的细胞质内。通过植入Balb / C裸鼠的OVCAR-3的肿瘤体积变化,通过三步法测定的负载pac的B-F127-PLA纳米粒子的体内抗肿瘤功效大于一步法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号